BPC+TB (BPC-157 & TB-500 Blend)

BPC+TB Blend is Signal Labs' dual-peptide tissue biology research preparation, containing BPC-157 (10mg) and TB-500 (10mg) co-lyophilised in a single vial at greater than or equal to 98% HPLC-verified purity for each component. The blend is formulated for researchers studying multi-pathway tissue biology where simultaneous coverage of nitric oxide/VEGF signalling (BPC-157) and actin dynamics/cell migration (TB-500) is the experimental objective, without the need to separately reconstitute and mix two individual vials.

BPC-157 (Body Protection Compound-157, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW 1419.56 g/mol) is a 15 amino acid synthetic peptide with documented stability in biological media attributable to its Pro-Pro-Pro polyproline II helix at positions 3-5. BPC-157's research profile centres on eNOS/NO signalling, VEGF and EGR-1 expression changes, FAK-paxillin pathway modulation in cell adhesion and migration models, and neurochemical system interactions including dopaminergic and serotonergic circuit research. The gastrointestinal cytoprotection biology of BPC-157 — derived from its origin as a gastric juice protein partial sequence — represents one of the most extensively published research areas, with over 100 peer-reviewed publications examining BPC-157 in gastric, intestinal, and hepatic models.

TB-500 (synthetic Thymosin Beta-4 analogue, 43 amino acids, MW 4963.5 g/mol) sequester G-actin monomers through its LKKTET hexapeptide motif at positions 17-22, directly regulating the cellular G/F-actin equilibrium. By maintaining a larger pool of sequestered G-actin available for rapid filament assembly at lamellipodia, TB-500 promotes directional cell migration — the mechanistic basis for its role in wound healing research. TB-500 also activates integrin-linked kinase (ILK) through a separate, actin-independent mechanism, connecting it to PI3K/Akt survival signalling in endothelial and epithelial models.

The complementary mechanism rationale for the BPC+TB blend is non-overlapping pathway coverage: BPC-157 operates through NO/VEGF/FAK-paxillin extracellular and membrane-proximal signalling, while TB-500 operates through cytoskeletal actin dynamics and ILK intracellular signalling. These represent distinct molecular entry points into tissue biology — vascular supply restoration (angiogenesis, BPC-157) and cellular repopulation of damaged areas (migration, TB-500) — that are both required for complete tissue repair but mechanistically separable using appropriate inhibitor controls.

For mechanistic dissection: L-NAME (NOS inhibitor) selectively blocks BPC-157's NO-dependent effects without affecting TB-500's actin biology; cytochalasin D (actin polymerisation inhibitor) disrupts TB-500's migration-promoting effects without directly impacting BPC-157's NO or VEGF signalling. Running full factorial experiments (vehicle, BPC-157 alone, TB-500 alone, combination blend) with these selective inhibitors allows rigorous attribution of any observed combined effect to individual pathway contributions.

Signal Labs supplies BPC-157 (10mg individual) and TB-500 (10mg individual) separately for single-compound mechanistic research. The Glow Blend extends the BPC+TB combination to three components by adding GHK-Cu (50mg), covering copper-dependent extracellular matrix biology alongside the NO/VEGF and actin pathways.

Total vial content: 20mg (10mg BPC-157 + 10mg TB-500). Reconstitute in bacteriostatic water at the desired total concentration. Both components dissolve readily to produce a clear colourless solution. Store lyophilised at -20°C. Aliquot after reconstitution; store at -20°C for up to 3 months. For laboratory and analytical research purposes only.

Full factorial experimental design (vehicle, BPC-157 alone, TB-500 alone, combination blend) with selective inhibitors — L-NAME for BPC-157's NO-dependent effects, cytochalasin D for TB-500's actin dynamics — provides rigorous mechanistic attribution for any observed combined effect. Bliss independence analysis (E(A+B) = E(A) + E(B) - E(A)×E(B)) determines whether effects are additive or synergistic. Total vial content: 20mg (10mg BPC-157 + 10mg TB-500). Reconstitute in bacteriostatic water at desired concentration. Both components dissolve readily to a clear, colourless solution. Store lyophilised at -20°C. Aliquot after reconstitution; stable at -20°C for 3 months. For laboratory and analytical research purposes only.